Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis (Q37853359)

24 August 2017

0 references

1 reference

title

Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis (English)

1 reference

inflammatory bowel diseases

24 August 2017

main subject

0 references

0 references

0 references

1 reference

1 reference

24 August 2017

Paul Moayyedi

0 references

William Jeffery Sandborn

series ordinal

object named as

William J Sandborn

1 reference

24 August 2017

Stephen B Hanauer

1 reference

24 August 2017

Nicholas J Talley

1 reference

24 August 2017

Khurram J Khan

1 reference

24 August 2017

language of work or name

English

0 references

publication date

15 March 2011

1 reference

The American Journal of Gastroenterology

24 August 2017

published in

1 reference

24 August 2017

volume

106

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

644-59, quiz 660

1 reference

Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Cortisone in ulcerative colitis; final report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Frequency of glucocorticoid resistance and dependency in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Systematic review: Infliximab therapy in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Adalimumab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.73

21 January 2018

Identifiers

DOI

10.1038/AJG.2011.73

1 reference

24 August 2017

1 reference